Zusammenfassung
Mehr als 5,5 Millionen Menschen sterben jährlich weltweit an den Folgen eines bösartigen Tumorleidens. Bis zum Jahr 2020 wird diese Zahl wahrscheinlich auf über 10 Millionen Menschen steigen, wobei den Entwicklungsländern ein Anteil von rund 70% zufällt. Nach Schätzung der Weltgesundheitsorganisation (WHO) ist der Tod als Folge eines bösartigen Tumorleidens bei 40–45% der Männer und 10–15% der Frauen ursächlich auf das chronische lnhalationsrauchen oder den Genuss von Tabakprodukten in anderer Form (Zigarren, Pfeife, Schnupftabak) zurückzuführen.Schätzungen gehen davon aus, dass bei einer weltweiten Reduzierung des Tabakkonsums diese Zahlen in den entwickelten Industrienationen um bis zu 30% sinken würden. Dabei sind mit dem Konsum von Tabakprodukten und der damit verbundenen Exposition gegenüber mehr als 50 sicher als kanzerogen identifizierten Inhaltsstoffen nicht nur bösartige Tumoren assoziiert: Neben chronisch-entzündlichen und destruktiven Lungenerkrankungen (chronische Bronchitis, Emphysem; Müller 1986) sind als direkt tabakkonsumassoziierte Todesursachen vornehmlich kardiovaskuläre Erkrankungen, besonders die koronare Herzkrankheit und der Myokardinfarkt, dokumentiert. Insgesamt wurde die Zahl der Toten 1995 als Folge des Abusus an Tabakprodukten von der WHO weltweit auf rund 1,9 Millionen (1.400.000 Männer; 500.000 Frauen) geschätzt. Andere Schätzungen gehen von jährlich rund 3 Millionen Toten weltweit aus (Boyle 1997).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Adlkofer F, Heller WD (1995) Exposure to environmental tobacco smoke and risk of lung cancer:The epidemiological evidence. Eur Resp J 8: 1240–1241
Bartsch H, Malaveille C, Friesen M, Kadlubar FF, Vineis P (1993) Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV: Molecular dosimetry studies implicate aromatic dimers as bladder carcinogens. EurJ Cancer 29A: 1199–1207
Bennett WP, Colby TV, Travis WD et al. (1993) p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 53:4817–4822
Blum A (1993) Curtailing the tobacco pandemic. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott-Raven, Philadelphia, pp 480–491
Blum A (1997) Cancer prevention: preventing tobacco-related cancers. In: DeVita VT, Hellman S, Rosenberg SA (eds.) Cancer: principles and practice of oncology. Lippincott-Raven, Philadelphia, pp 545–55
Bouchardy C, Benhamou S, Dayer P (1996) The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 56: 251–253
Boyle P (1997) Cancer, cigarette smoking and premature death in Europe: a review including the recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Lung Cancer 17: 1–60
Brennan JA, Boyle JO, Koch WM,Goodman SN, Hruban RH, EbyYJ,Couch MJ, Forastiere AA, Sidransky D (1995) Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 712–717
Brownson RC, Novotny TE, Perry MC (1993) Cigarette smoking and adult leukemia:a meta-analysis. Arch Int Med 153: 469–475
Burch JD, Rohan TE, Howe GR, Risch HA, Hill GB, Steele R, Miller AB (1989) Risk of bladder cancer by source and type of tobacco exposure:a case control study. Int J Cancer 44: 622–628
Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW (1994) Cigarette smok- ing and risk of fatal breast cancer. Am J Epidemiol 139: 1001–1007
Denissenko MF, Pao A, Tang M, Pfeifer GP (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274: 430–432
Flanders WD, Rochman KJ (1982) Interaction of alcohol and tobacco in laryngeal cancer.Am J Epidemiol 115: 371–379
Fontanini G,Vignati S, Bigini D, Merlo GR, Ribecchini A,Angeletti CA, Baso-lo F, Pingitore R, Bevilacqua G (1994) Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression.] Pathol 174: 23–31
Fontham ETH, Correa P, Reynolds P et al. (1994) Environmental tobacco smoke and lung cancer in nonsmoking women: a multicenter study. JAMA 271: 1752–1759
Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.Cancer Res 54: 4855–4878
Hartge P, Silverman D, Hoover R, Schairer C, Altman R, Austin D, Cantor K, Child M, Key K, Marrett LD (1987) Changing cigarette habits and bladder cancer risk: a case control study. J Nat Cancer Inst 78: 1119–1125
Hietanen E, Husgafvel-Pursiainen K, Vainio H (1997) Interaction between dose and susceptibility to environmental cancer: a short review. Environ Health Perspect 105 [Suppl 4]: 749–754
Holly EA, Petrakis NL, Friend NF, Sarles DL, Lee RE, Flander LB (1986) Muta-genic mucus in the cervix of smokers. J Nat Cancer Inst 76: 983–986
Horn-Ross PL, Ljung BM, Morrow M (1997) Environmental factors and the risk of salivary gland cancer. Epidemiology 8: 414–419
Horwitz RI, Smaldone LF, Viscoli CM (1988) An ecogenetic hypothesis for lung cancer in women. Arch Int Med 148: 2609–2612
Hussain SP, Harris CC (1998) Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 58: 4023–4037
Johnson B,Kelley M (1993) Overview of genetic and molecular events in the pathogenesis of lung cancer. Chest 103: 1–3
Kagan E, Brody AR (1996) Immunopathology of asbestos-related lung disease.ln: Kradin RL, Robinson BWS (eds) Immunopathology of lung disease. Butterworth-Heinemann, Boston, pp 421–443
Kaufman JA, Burke Ai (1997) The etiology and pathogenesis of laryngeal carcinoma. Otolaryngol Clin North Am 30: 1–19
Koutsky LA, Galloway DA, Holmes KK (1988) Epidemiology of genital human papillomavirus infection. Epidemiol Rev 10: 122–163
Müller K-M (1986) Lungenbefunde und Rauchgewohnheiten-Pathologische Anatomie. In: Geisler LS (Hrsg) Rauchen und Atemwege-Präventive und therapeutische Aspekte. Verlag für angewandte Wissenschaften, München, S 65–84
Muller K-M (1994) Kehlkopfkarzinom-Pathologische Anatomie. In: Hauptverband der gewerblichen Berufsgenossenschaften (HVBG) (eds) Larynxkarzinom durch Asbest?-BK-Report 2/94. Hauptverband der gewerblichen Berufsgenossenschaften, Sankt Augustin, S 37–46
Müller K-M, Krohn BR (1980) Smoking habits and their relationship to pre-cancerous lesions of the Iarynx.J Cancer Res Clin Oncol 96: 211–217
Müller K-M,Wiethege Th, Krismann M,Junker K (2002) Molekulare Pathologie bösartiger pulmonaler und pleuraler Tumoren, Teil. 1: Pulmonale Tumoren. In: Ruckpaul D,Ganten D (eds) Handbuch der molekularen Medizin, Bd. 10. Springer, Berlin Heidelberg New York Tokyo, S. 29–64
Müller K-M, Wiethege Th, Tolnay E, Junker K (1997) Variable Biologie der Lungentumoren-Prognosefaktoren durch den Pathologen? Atemw Lungenkrkh 23: 302–307
Newcomb PA, Storer BE, Marcus PM (1995) Cigarette smoking in relation to risk of large bowel cancer in women. Cancer Res 55: 4906–4909
Parkin DM, Pisani P, Lopez AD, Masuyer E (1994) At least one in seven cases of cancer is caused by smoking.Global estimates for 1985. Int J Cancer 59: 494–504
Pisani P, Parkin DM, Ferlay J (1993) Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 55: 891–903
Pryor WA (1997) Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity. Environ. Health Perspect 105 [Suppl 4]: 875–882
Rakel RE, Blum A (1990) Nicotine addiction. In: Rakel RE (ed) Textbook of family practice.4th edn.WB Saunders, Philadelphia, pp 1612–23
Randerath E, Randerath K (1993) Monitoring tobacco smoke-induced DNA damage by 32P-postlabelling.IARC Sci Publ 124: 305–314
Redmond DE (1970) Tobacco and cancer:The first clinical report, 1761. N Engl J Med 282: 18–23
Reynolds P, Fontham ETH (1995) Passive smoking and lung cancer. Ann Med 27: 633–640
Rosell R, Li S, Skacel Z, Mate JL, Maestre J, Canela M, Tolosa E, Armengol P, Barnadas A, Ariza A (1993) Prognostic impact of mutated K-ras gene in surgically resected non- small cell lung cancer patients. Oncogene 8: 2407–2412
Ruggeri BA, Bauer B, Zhang SY, Kleinszanto AJP (1994) Murine squamous cell carcinoma cell lines produced by a complete carcinogenesis protocol with benzo[a]pyrene exhibit characteristic p53 mutations and the absence of H-ras and cyl 1/cyclin D1 abnormalities. Carcinogenesis 15: 1613–1619
Rusch V, Klimstra D, Linkov I, Dmitrovsky E (1995) Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development. Cancer Res 55: 1365–1372
Sasson IM, Haley M, Hoffmann D, Wynder EL, Hellberg D, Nilsson S (1985) Cigarette smoking and neoplasia of the uterine cervix: Smoke constituents in cervical mucus. N Engl J Med 312: 315–316
Schottenfeld D (1984) Epidemiology of cancer of the esophagus. Semin. Oncol. 1 1: 92–100
Schottenfeld D, Gantt RC,Wynde EL (1974) The role of alcohol and tobacco in multiple primary cancers of the upper digestive system, larynx,and lung: A prospective study. Prey. Med. 3: 277–93
Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N, Mooi WJ (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. EngI.J Med 323: 561–5
Soussi T (1996) The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Mol. Med.Today 32–7
Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Ueda R (1992) p53 mutations in non-small cell lung cancer in Japan:association between mutations and smoking. Cancer Res 52: 734–736
Suzuki K, Nagai K, Yoshida J, Nishimura M,Takahashi K,YokoseT, Nishiwaki Y (1999) Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. Cancer 86: 1976–84
Thomas M (1997) Tumorassoziierte Prognoseparameter beim nicht-kleinzelligen Bronchialkarzinom. Pneumologie 51: 669–677
Tredaniel J, Boffetta P, Buiatti E, Saracci R, Hirsch A (1997) Tobacco smoking and gastric cancer: review and meta-analysis. Int J Cancer 72: 565–473
Tseng JE, Rodriguez M, Ro J, Liu D, Hong WK, Mao L (1999) Gender differences in p53 mutational status in small cell lung cancer.Cancer Res 59: 5666–5970
US Department of Health and Human Services (1982) The health consequences of smoking: Cancer: A report of the Surgeon General. Washington DC, US Department of Health and Human Services. Office on Smoking and Health 82–50179
US Department of Health and Human Services. The health consequences of using smokeless tobacco: A report of the Advisory Committee to the Surgeon General. Washington DC, US Department of Health and Human Services, Public Health Service, NIH, (1986) 86–2874
US Department of Health EaW. Smoking and health: A report of the Surgeon General.Washington DC, Public Health Service, Office of the Assistant Secretary for Health, Office on Smoking and Health, (1979) 79–50066
WiethegeT, Junker K, Johnen G, Krismann M, Müller K-M (2000) Pathologie und Molekularbiologie bösartiger pulmonaler Tumoren. Pathologe 21: 404–423
Williams RR, Horn JW (1977) Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients:Interview study from the Third National Cancer Survey. J. Nat Cancer Inst 58: 525–475
Wyser C, Bolliger CT (1997) Smoking-related disorders. In: Bolliger CT, Fagerström KO (eds) The tobacco epidemic. Karger, Basel, S. 78–106
Zang EA, Wynder EL (1996) Differences in lung cancer risk between men and women: examination of the evidence. J. Nat. Cancer Inst. 88: 183–192
Rights and permissions
Copyright information
© 2004 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Müller, KM., Wiethege, T. (2004). Rauchen und Krebs. In: Die Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-06670-6_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-06670-6_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-06671-3
Online ISBN: 978-3-662-06670-6
eBook Packages: Springer Book Archive